EGFR and squamous cell carcinoma: Almost all patients with EGFR-positive NSCLC had adenocarcinomas (386 patients [99.2%]) whereas 56 patients with wildtype EGFR NSCLC (16.8%) had squamous cell carcinoma (P < .001).